GlassScriptPhysician profile
Judith K Waters
NPI 1134106974
$7,856.25
in general payments reported to CMS, 2019-2025
46 companies · $744 in 2025
The $744 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $1,215 · 2021: $1,581 · 2022: $737 · 2023: $1,633 · 2024: $1,337 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,620 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,620.16 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,006.80 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $993.60 | 2019-2025 | Ubrelvy, Vraylar, Synthroid |
| Lilly USA, LLC | $571.78 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Novo Nordisk INC | $535.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $469.64 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $311.57 | 2019-2024 | Spravato |
| Merck Sharp & Dohme LLC | $280.92 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Glaxosmithkline, LLC. | $280.16 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $276.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $260.65 | 2021-2024 | |
| Amarin Pharma, INC. | $252.14 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $252.03 | 2021-2024 | Xifaxan, Trulance |
| Astellas Pharma US INC | $234.42 | 2019-2023 | Myrbetriq, Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.94 | 2019-2025 | Jardiance, Tradjenta |
| Takeda Pharmaceuticals U.S.A., INC. | $199.13 | 2019-2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Waters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.